breast cancer. Malignant neoplasm of breast
Conditions
Interventions
Patients who meet the treatment criteria are scheduled for two to four cycles of treatment with the radiopharmaceutical Lu177-FAPI-2286, manufactured by Pars Isotope Company. Response and side effects
Sponsors
Shiraz University of Medical Sciences
Parsisotope Company
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Advanced refractory breast cancer Positive lesions on FAPI imaging Glomerular filtration rate (GFR)>30 ml/min Hemoglobulin (Hb) > 9 g/dl Blood White blood cell count (WBC)>3500/microliter Blood Plateletes count >75000/micrliter Liver enzymes within 2 times of normal limit Patient's consent and awareness to participate in the study
Exclusion criteria
Exclusion criteria: Eastern cooperative oncology group (ECOG) performance score>2 Concomitant other malignancy or other end-organ disease pregnancy and breast feeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hemoglobulin. Timepoint: Before treatment and 2 weeks and 4 weeks after each treatment cycle. Method of measurement: As part of a complete blood cell count (CBC) using spectrometry.;Glomerular filtration rate. Timepoint: Before treatment and 2 weeks and 4 weeks after each treatment cycle. Method of measurement: Cockroft formula.;Response to treatment. Timepoint: After 4 cycles of therapy. Method of measurement: Anatomic imaging and diagnostic FAPI scan.;White blood cell count. Timepoint: Before treatment and 2 weeks and 4 weeks after each treatment cycle. Method of measurement: Cell counter.;Platelets. Timepoint: Before treatment and 2 weeks and 4 weeks after each treatment cycle. Method of measurement: Cell counter. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactTahereh Ghaedian
Shiraz University of Medical Sciences
Outcome results
None listed